Information Provided By:
Fly News Breaks for May 16, 2016
NVS, PFE, ANAC
May 16, 2016 | 14:33 EDT
JMP Securities analyst Donald Ellis calculated a fair value estimate of Anacor Pharmaceuticals (ANAC) of $130 per share and said he sees Novartis (NVS), which already owns 50% of U.S. Kerydin sales, as the most likely company to make a competing bid. Pfizer (PFE) announced this morning a definitive agreement to acquire Anacor for $99.25 per share.
News For ANAC;PFE;NVS From the Last 2 Days
NVS, PFE
Jul 20, 2019 | 07:27 EDT
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump and his administration with this weekly recap compiled by The Fly: 1. PENTAGON'S CLOUD-COMPUTING CONTRACT:... To see the rest of the story go to thefly.com. See Story Here